You can find other events in our calendar, or use the search:
International Lung Cancer Congress
Huntington Beach, United States 19 – 22 July / 2012
Get entrance ticket to the trade show in advance. Choose the number of tickets, fill in a form and get them to your email.
|Free||− 1 +|
Unfortunately, we ran out of tickets and sincerely apologise for the inconvenience. But we have exhibitions you might like to attend.
This is a past event.
About the trade show
The Sixth Annual New York Lung Cancer Symposium brings the key data from international oncology conferences to attending physicians. The importance of molecular pathology in diagnosis and treatment decision making will be emphasized, followed by other current topics of interest, such as maintenance therapy. The optimization of adjuvant therapy for patients with early-stage NSCLC and chemoradiation therapy for patients with locally advanced NSCLC will be reviewed. Management of patients with specific molecular defects such as EGFR mutations or the EML4-ALK fusion gene will also be discussed. Didactic lectures from lung cancer experts will set the stage for case-based panel discussions and opportunities for participants to interact with faculty. A multidisciplinary tumor board will discuss current advances and issues in locally advanced NSCLC. The symposium will also feature a case discussion session in which fellows can actively participate and thereby enhance their learning experience.
This educational program is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer are also invited to attend.
At the conclusion of this symposium, you should be able to:
- Assess molecular profiling of lung cancer based on tumor characteristics
- Summarize the optimal approach to adjuvant chemotherapy for patients with early-stage NSCLC
- Discuss the efficacy and toxicity of combined modality regimens in locally advanced NSCLC
- Analyze approaches to optimize the use of EGFR inhibitors in patients with EGFR mutations
- Evaluate clinical data on maintenance therapy with cytotoxic/targeted agents in advanced NSCLC
- Assess clinical data on novel agents in development for lung cancer
- Assess potential benefits of clinical trials for individual patients with lung cancer